3. HIV positive patients. 
4. Severe systemic diseases considered to be indicative of an unacceptable 
anesthetic/operative risk. 
5. Multiple or bilateral tumors. Brain stem tumors. 
6. Tumors greater than 4 cm in any diameter. 
7. Patients with tumor cavities that are likely to communicate with either a 
subarachnoid cistern or the ventricular system. 
8. High titers of antibodies to adenovirus. 
TREATMENT AND EVALUATION SCHEDULE 
B-ofitr * 
h rua 
rtfecton 
Into* 
treatment 
lot thmof 
J 1 
-n 
Pre- 
treatmente 
•rakjaDon 
I— * 
-1 
GCV. Mr. *. a. Me. 
* '■Cl. Me Mr. Ph. Jm 
I I 
0 1 
HOSPITALIZATION 
months 
Mr«Pft MrtPfi Mr i Ph Mr & Ph 
till 
J 1 1 
2 4 6 8 
Q CV • GCV frcatm«nt. Mr «MRi. Pti ■ phy»*c»J e««m; CJ • dime*! Im • bivnunologicat 
t«ts Me ■ m*crot>iotog»caMe«ti N ■ nexjropsychologtcsJ test* 
II. Patient Evaluation 
A. Evaluations Prior to Surgery. 
1 . The following evaluations must be performed by the neurosurgery and 
anesthesiology services within 30 days of the treatment to determine eligibility. A 
complete history detailing all symptoms and previous treatments and physical 
examination including documentation of signs and symptoms of tumor and 
neurological deficits. Height, weight, and body surface area will be recorded. 
2. Hematology: CBC, platelet count, reticulocyte count, PT, PTT, fibrinogen 
3. Chemistries: BUN, creatinine, Na, K, Cl, C0 2 , calcium, phosphorus, magnesium, 
LDH, SGOT, SGPT, GGT, bilirubin, CPK 
4. Urinalysis 
5. Chest X-ray : PA and Lateral 
6. Diagnostic imaging : MRI and/or CT of brain. 
7. Pathology review - Reports, slides and, if possible, blocks will be reviewed by Dr. J. 
Clay Goodman. 
Recombinant DNA Research, Volume 20 
